Mereo BioPharma Group plc financial data

Symbol
MREO on Nasdaq
Industry
Pharmaceutical Preparations
Location
One Cavendish Place, Fourth Floor, London, United Kingdom
State of incorporation
United Kingdom
Fiscal year end
December 31
Latest financial report
10-K - Q4 2024 - Mar 26, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 567 %
Debt-to-equity 24.4 %
Return On Equity -67.9 % -14.7%
Return On Assets -54.5 %
Operating Margin -3.92K %

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 795M shares +13.4%
Entity Public Float 471M USD +228%
Common Stock, Value, Issued 3.06M USD +10.2%
Weighted Average Number of Shares Outstanding, Basic 740M shares +12.2%
Weighted Average Number of Shares Outstanding, Diluted 740M shares +12.2%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 0 USD -100%
Research and Development Expense 20.9M USD +20.2%
General and Administrative Expense 26.4M USD +43.5%
Operating Income (Loss) -47.4M USD -66.7%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -43.3M USD -44.2%
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -43.3M USD -46.8%
Earnings Per Share, Basic -0.06 USD/shares -50%
Earnings Per Share, Diluted -0.06 USD/shares -50%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 69.8M USD +21.6%
Assets, Current 74.8M USD +17.3%
Property, Plant and Equipment, Net 257K USD -36.5%
Operating Lease, Right-of-Use Asset 727K USD -41.6%
Intangible Assets, Net (Excluding Goodwill) 1.09M USD
Assets 76.4M USD +14.9%
Accounts Payable, Current 2.44M USD +4.01%
Accrued Liabilities, Current 4.07M USD -25.5%
Liabilities, Current 13.8M USD +46%
Operating Lease, Liability, Noncurrent 187K USD -79.4%
Other Liabilities, Noncurrent 565K USD -26%
Liabilities 15.4M USD -3.39%
Accumulated Other Comprehensive Income (Loss), Net of Tax -18.8M USD -7.8%
Retained Earnings (Accumulated Deficit) -463M USD -10.3%
Stockholders' Equity Attributable to Parent 61M USD +20.6%
Liabilities and Equity 76.4M USD +14.9%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -7.99M USD +13.6%
Net Cash Provided by (Used in) Investing Activities -700K USD -67.1%
Common Stock, Shares, Issued 776M shares +10.6%
Common Stock, Par or Stated Value Per Share 0 GBP/shares 0%
Interest Paid, Excluding Capitalized Interest, Operating Activities 4K USD -99.4%
Deferred Tax Assets, Valuation Allowance 215M USD +4.21%
Deferred Tax Assets, Gross 215M USD +4.21%
Operating Lease, Liability 894K USD -42.6%
Depreciation 143K USD -16.4%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -44.6M USD -76.6%
Lessee, Operating Lease, Liability, to be Paid 958K USD
Property, Plant and Equipment, Gross 1.21M USD +0.08%
Operating Lease, Liability, Current 707K USD +8.44%
Operating Lease, Weighted Average Discount Rate, Percent 0.1 pure 0%
Deferred Tax Assets, Operating Loss Carryforwards 118M USD +6.33%
Operating Lease, Payments 780K USD +2.77%
Additional Paid in Capital 540M USD +11%
Amortization of Intangible Assets 108K USD +68.8%
Deferred Tax Assets, Net of Valuation Allowance 0 USD
Operating Leases, Future Minimum Payments Due 1.54M USD
Interest Expense 1.37M USD -52.4%